Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis

Henry A. Leder, Douglas A. Jabs, Anat Galor, James P. Dunn, Jennifer E. Thorne

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: To describe the effectiveness of periocular corticosteroid injections in the treatment of cystoid macular edema (CME) complicating noninfectious uveitis. Design: Retrospective cohort study. Methods: A total of 126 patients (156 eyes) were evaluated for presence of CME, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications. Main outcome measures included resolution of CME and visual acuity at the 1- and 3-month visits, failure of periocular injection therapy, and side effects. Results: Twenty-eight percent of the 156 eyes had anterior uveitis, 22% intermediate uveitis, and 31% panuveitis. Of these eyes, 53% demonstrated clinical resolution of CME at 1 month and 57% at 3 months after a single periocular corticosteroid injection. Forty eyes were treated with >1 periocular injection because the CME persisted 1 month after the first injection (1 additional injection in 21 eyes; 2 additional injections in 14 eyes; >2 additional injections in 5 eyes). For the 21 eyes treated with a second periocular corticosteroid injection, 81% had no CME 1 month after the second injection and 48% had no CME 3 months after the second injection. Twenty-three eyes (15%) failed periocular corticosteroid therapy. Of eyes initially responding to periocular injection, CME recurred in 53% (median time to recurrence = 20.2 weeks). A halving of the visual angle was observed in 52% and 57% at the 1- and 3-month visits after injection, respectively. Conclusions: Fifty-three percent of eyes treated with a single periocular corticosteroid injection had clinical resolution of CME 1 month after the injection.

Original languageEnglish
Pages (from-to)441-448
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume152
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Triamcinolone Acetonide
Macular Edema
Uveitis
Intraocular Injections
Injections
Adrenal Cortex Hormones
Visual Acuity
Intermediate Uveitis
Panuveitis
Anterior Uveitis
Intraocular Pressure
Cohort Studies
Therapeutics
Retrospective Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. / Leder, Henry A.; Jabs, Douglas A.; Galor, Anat; Dunn, James P.; Thorne, Jennifer E.

In: American Journal of Ophthalmology, Vol. 152, No. 3, 01.09.2011, p. 441-448.

Research output: Contribution to journalArticle

Leder, Henry A. ; Jabs, Douglas A. ; Galor, Anat ; Dunn, James P. ; Thorne, Jennifer E. / Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. In: American Journal of Ophthalmology. 2011 ; Vol. 152, No. 3. pp. 441-448.
@article{6098959b63824502b24de2861570d4c5,
title = "Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis",
abstract = "Purpose: To describe the effectiveness of periocular corticosteroid injections in the treatment of cystoid macular edema (CME) complicating noninfectious uveitis. Design: Retrospective cohort study. Methods: A total of 126 patients (156 eyes) were evaluated for presence of CME, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications. Main outcome measures included resolution of CME and visual acuity at the 1- and 3-month visits, failure of periocular injection therapy, and side effects. Results: Twenty-eight percent of the 156 eyes had anterior uveitis, 22{\%} intermediate uveitis, and 31{\%} panuveitis. Of these eyes, 53{\%} demonstrated clinical resolution of CME at 1 month and 57{\%} at 3 months after a single periocular corticosteroid injection. Forty eyes were treated with >1 periocular injection because the CME persisted 1 month after the first injection (1 additional injection in 21 eyes; 2 additional injections in 14 eyes; >2 additional injections in 5 eyes). For the 21 eyes treated with a second periocular corticosteroid injection, 81{\%} had no CME 1 month after the second injection and 48{\%} had no CME 3 months after the second injection. Twenty-three eyes (15{\%}) failed periocular corticosteroid therapy. Of eyes initially responding to periocular injection, CME recurred in 53{\%} (median time to recurrence = 20.2 weeks). A halving of the visual angle was observed in 52{\%} and 57{\%} at the 1- and 3-month visits after injection, respectively. Conclusions: Fifty-three percent of eyes treated with a single periocular corticosteroid injection had clinical resolution of CME 1 month after the injection.",
author = "Leder, {Henry A.} and Jabs, {Douglas A.} and Anat Galor and Dunn, {James P.} and Thorne, {Jennifer E.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ajo.2011.02.009",
language = "English",
volume = "152",
pages = "441--448",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis

AU - Leder, Henry A.

AU - Jabs, Douglas A.

AU - Galor, Anat

AU - Dunn, James P.

AU - Thorne, Jennifer E.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Purpose: To describe the effectiveness of periocular corticosteroid injections in the treatment of cystoid macular edema (CME) complicating noninfectious uveitis. Design: Retrospective cohort study. Methods: A total of 126 patients (156 eyes) were evaluated for presence of CME, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications. Main outcome measures included resolution of CME and visual acuity at the 1- and 3-month visits, failure of periocular injection therapy, and side effects. Results: Twenty-eight percent of the 156 eyes had anterior uveitis, 22% intermediate uveitis, and 31% panuveitis. Of these eyes, 53% demonstrated clinical resolution of CME at 1 month and 57% at 3 months after a single periocular corticosteroid injection. Forty eyes were treated with >1 periocular injection because the CME persisted 1 month after the first injection (1 additional injection in 21 eyes; 2 additional injections in 14 eyes; >2 additional injections in 5 eyes). For the 21 eyes treated with a second periocular corticosteroid injection, 81% had no CME 1 month after the second injection and 48% had no CME 3 months after the second injection. Twenty-three eyes (15%) failed periocular corticosteroid therapy. Of eyes initially responding to periocular injection, CME recurred in 53% (median time to recurrence = 20.2 weeks). A halving of the visual angle was observed in 52% and 57% at the 1- and 3-month visits after injection, respectively. Conclusions: Fifty-three percent of eyes treated with a single periocular corticosteroid injection had clinical resolution of CME 1 month after the injection.

AB - Purpose: To describe the effectiveness of periocular corticosteroid injections in the treatment of cystoid macular edema (CME) complicating noninfectious uveitis. Design: Retrospective cohort study. Methods: A total of 126 patients (156 eyes) were evaluated for presence of CME, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications. Main outcome measures included resolution of CME and visual acuity at the 1- and 3-month visits, failure of periocular injection therapy, and side effects. Results: Twenty-eight percent of the 156 eyes had anterior uveitis, 22% intermediate uveitis, and 31% panuveitis. Of these eyes, 53% demonstrated clinical resolution of CME at 1 month and 57% at 3 months after a single periocular corticosteroid injection. Forty eyes were treated with >1 periocular injection because the CME persisted 1 month after the first injection (1 additional injection in 21 eyes; 2 additional injections in 14 eyes; >2 additional injections in 5 eyes). For the 21 eyes treated with a second periocular corticosteroid injection, 81% had no CME 1 month after the second injection and 48% had no CME 3 months after the second injection. Twenty-three eyes (15%) failed periocular corticosteroid therapy. Of eyes initially responding to periocular injection, CME recurred in 53% (median time to recurrence = 20.2 weeks). A halving of the visual angle was observed in 52% and 57% at the 1- and 3-month visits after injection, respectively. Conclusions: Fifty-three percent of eyes treated with a single periocular corticosteroid injection had clinical resolution of CME 1 month after the injection.

UR - http://www.scopus.com/inward/record.url?scp=80051913900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051913900&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2011.02.009

DO - 10.1016/j.ajo.2011.02.009

M3 - Article

C2 - 21652023

AN - SCOPUS:80051913900

VL - 152

SP - 441

EP - 448

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -